Abstract

This updated position paper on Japanese encephalitis (JE) vaccines replaces the 2006 position paper on this subject; it focuses on new information concerning the availability, safety, immunogenicity and effectiveness of JE vaccines and the duration of protection they confer. Recent data on global prevalence and burden of disease caused by JE and cost-effectiveness considerations regarding JE vaccination are also summarized. Recommendations on the use of JE vaccines were discussed by SAGE in October 2014.

  • Position paper
  • SAGE
  • Japanese encephalitis